ECE2020 Audio ePoster Presentations Diabetes, Obesity, Metabolism and Nutrition (285 abstracts)
Effectiveness of PCSK9 inhibitors in familial hypercholesterolemia in asturias, spain
Silvia González Martínez 1 , Raul Rodriguez Escobedo 2 , Juan Luis Fernández Morera 2 , Alfonso José López Alba 1 , José Antonio Álvarez Tamargo 3 , Carlos José Lamela Piteira 4 & Francisco Villazón González 2
1Hospital Vital Álvarez-Buylla, Endocrinology, Santullano, Spain; 2Central University Hospital of Asturias, Endocrinology, Oviedo, Spain; 3Hospital Vital Álvarez-Buylla, Cardiology, Santullano, Spain; 4Hospital Vital Álvarez-Buylla, Hospital Pharmacy, Santullano, Spain
Introduction: Familial hypercholesterolemia (FH) is a genetic disorder characterized by high levels of LDL cholesterol (LDL-C) from birth. Treatment with statins and ezetimibe achieves in most cases large reductions in LDL-C. In those patients in whom the reduction in LDL-C is insufficient or who have intolerance to such treatments, the appearance of PCSK9 inhibitors has been an effective and safe alternative to achieve the LDL-C objectives.
Materials and methods: The results of the lipid profile of patients with FH treated with PCSK9 inhibitors in healthcare areas IV and VII of Asturias (Spain) were retrospectively analyzed. The indications for its use are those included in the consensus document of the Spanish Society of Atherosclerosis (2016).
Results: Data were obtained from 46 patients with FH treated with PCSK9 inhibitors, with a mean follow-up of 20.6 months. The average age was 59.13 years, with a similar distribution by sex (52.2% male).
| TC (mg/dl) | LDL-C (mg/dl) | HDL-C (mg/dl) | TG (mg/dl) | |
| Initial | 264,5 | 189 | 45 | 124 |
| 2 months | 139 | 67 | 47 | 115 |
| 6 months | 160 | 75 | 46 | 111 |
| 12 months | 159 | 75 | 50 | 102,5 |
| 24 months | 165 | 80 | 51 | 103 |
| TC | LDL-C | HDL-C | TG | |
| 2 months | – 47,45% | – 64,55% | + 4,44% | – 7,26% |
| 6 months | – 39,5% | – 60,32% | + 2,22% | – 10,48% |
| 12 months | – 39,89% | – 60,32% | + 11,11% | – 17,34% |
| 24 months | – 37,62% | – 57,67% | + 13,33% | – 16,94% |
Conclusions: PCSK9 inhibitors are an effective treatment alternative for patients with FH. Although its maximum effect is achieved 2 months after the start of treatment, its effect is maintained at 2 years, with LDL- C reductions of more than 55%. Likewise, there is a slight increase in HDL-C and a moderate decrease in TG.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more